000			04541nam a22005055i 4500
999			_c200457130 _d75342
003			DE-He213
005			20231109085750.0
007			cr nn 008mamaa
008			221130s2022 sz | s |||| 0|eng d
020			_a9783031044021
024	7		_a10.1007/978-3-031-04402-1 _2doi
040			_aTR-AnTOB _beng _cTR-AnTOB _erda
060		4	_aQZ 267
072		7	_aMJCL _2bicssc
072		7	_aMED062000 _2bisacsh
072		7	_aMJCL _2thema
096			_aQZ267EBK
245	1	0	_aCancer Drug Safety and Public Health Policy _h[electronic resource] : _bA Changing Landscape / _cedited by Charles Bennett, Courtney Lubaczewski, Bartlett Witherspoon.
250			_a1st ed. 2022.
264		1	_aCham : _bSpringer International Publishing : _bImprint: Springer, _c2022.
300			_a1 online resource
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	1		_aCancer Treatment and Research, _x2509-8497 ; _v184
505	0		_aFluoroquinolone-Associated Disability and Other Fluoroquinolone Associated Serious Adverse Events: Unexpected Toxicities Have Emerged in Recent Years -- Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse Reactions -- Policing of Drug Safety Information under the False Claims Act -- Translating Research Into Health Policy: The Citizen Petition Experience with the Food and Drug Administration -- Systemic Barriers and Potential Concerns from Reporting Serious Adverse Drug Reactions -- Was there Something Rotten in Denmark: Nephrogenic System Fibrosis Cases Occuring in Copenhagen -- Rituximab-associated Progressive Multifocal Leukoencephalopathy: A fatal adverse drug reaction -- Maximum Accuracy Machine Learning Statistical Analysis – A Novel Approach -- Investigating Severe Adverse Reactions: Examples of the ANTICIPATE Methodology at Work -- Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR) -- Moderna, Pfizer-BioNTech, and Johnson & Johnson/Janssen Post-Covid Vaccine Hematological Adverse Events Including Cerebral Venous Sinus Thrombosis (CVST), Thrombotic Thrombocytopenia (VITT), Blood Clots, Increased Vaginal/Menstrual Bleeding and/or Miscarriage, Stillbirth Delivery, or Premature Birth -- Investigating Novel Genetic Fluoroquinolone Associated Disorders.
520			_aThis book offers a wide-ranging description and analysis of recent developments and current trends in health policy with regard to cancer drug safety. The book opens with an overview of pharmacovigilance for cancer blockbuster drugs, covering both general considerations and efforts to develop a structured framework for the identification and reporting of adverse drug reactions (ADRs). A number of important examples of serious ADRs to hematology and oncology drugs are then reviewed, with evaluation of the lessons learned and the policy implications of the ensuing legal cases and their settlements. Further, the difficulty of reporting such blockbuster side effects in the medical literature is explored in an empirical study. Significant advances have been achieved in analytic methods for the identification of ADRs, and here there is a particular focus on the value of optimal discriminant analysis. Finally, the impacts on pharmacovigilance and drug safety of the huge fines paid under the U.S. False Claims Act relating to the defrauding of governmental programs also receive careful attention – these fines are playing an important role in changing the landscape for pharmaceutical safety.
650		0	_aOncology.
650		0	_aPharmacovigilance.
650	1	4	_aOncology.
650	2	4	_aDrug Safety and Pharmacovigilance.
700	1		_aBennett, Charles. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aLubaczewski, Courtney. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aWitherspoon, Bartlett. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt
710	2		_aSpringerLink (Online service)
830		0	_aCancer Treatment and Research, _x2509-8497 ; _v184
856	4	0	_uhttps://doi.org/10.1007/978-3-031-04402-1 _3Springer eBooks _zOnline access link to the resource
942			_2NLM _cEBK
041			_aeng